


Phosphate Replacement Guideline



PHOSPHATE

PRESENTATION:	<p>Addiphos 20ml vials containing 40mmol phosphate, 30mmol sodium and 30mmol potassium.</p> <p>Phosphate 500ml polyfusor containing 50mmol phosphate, 9.5mmol potassium and 81mmol sodium.</p> <p>Potassium acid phosphate 10ml ampoules containing 10mmol phosphate (1mmol/ml) and 10mmol potassium.</p> <p>Sodium glycerophosphate 20ml ampoules containing 20mmol phosphate (1mmol/ml) and 40mmol sodium.</p>
INDICATION:	<p>Hypophosphataemia.</p> <p>See previous page.</p>
DOSE AND ADMINISTRATION:	<p>Addiphos:</p> <ul style="list-style-type: none"> - Central IV administration: 20ml Addiphos made up to 60ml with glucose 5% over 6 hours. - Peripheral IV administration 20ml Addiphos made up to 500ml with glucose 5% over 6 hours. <p>Phosphate polyfusor:</p> <ul style="list-style-type: none"> - Central or peripheral IV administration: 500ml polyfusor administered over 12 hours (Can be given centrally over 6 hours if required). <p>If hypernatraemia a concern: Potassium Acid Phosphate</p> <ul style="list-style-type: none"> - Central IV administration: 40ml made up to 60ml with glucose 5% over 6 hours. <p>If hyperkalaemia a concern: Sodium Glycerophosphate:</p> <ul style="list-style-type: none"> - Central IV administration: 40ml made up to 60ml with glucose 5% over 6 hours. - Peripheral IV administration: 40ml made up to 500ml with glucose 5% over 8 hours.
STABILITY:	Physically and chemically stable for 24 hours at room temperature.

References:

- 1) UKCPA Minimum Infusion Volumes, Fourth Edition, December 2012. Accessed December 2020. <https://www.scottishintensivecare.org.uk/uploads/2014-07-24-19-56-30-Minimuminfusionvolumesinl-40262.pdf>
- 2) Injectable Medicines Guide, Medusa, accessed December 2020. <https://medusa.wales.nhs.uk/Home.asp>
- 3) Sodium Glycerophosphate, Summary of product characteristics, Fresenius Kabi. Updated March 2017. Accessed December 2020. https://www.fresenius-kabi.com/nz/documents/Glycophos_Datasheet.pdf
- 4) Sterile Potassium Acid Phosphate, Martindale Pharmaceuticals, SPC, updated January 2015. Accessed December 2020. <https://www.medicines.org.uk/emc/product/3572/smpc#gref>
- 5) Anecdotal experience in Critical Care units in NHS Lothian since 2010.
- 6) Personal communication with Fresenius-Kabi Medicines Information regarding stability of products 02/2014.
- 7) Personal communication with Fresenius –Kabi Medicines Information regarding stability of products 09/2015.

Title: Phosphate	
ID: Version 3	Authors: E Tang, C Hannah, G Smyth, A Neally, M Cromarty, H Veitch.
Status Draft/Final: FINAL	Approved by: Lothian Critical Care QIT Editorial Group.
	Written: January 2022
Updated on: January 2022	Next review : January 2024